BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20220101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230502
DTEND;VALUE=DATE:20230505
DTSTAMP:20260516T055807
CREATED:20230111T113431Z
LAST-MODIFIED:20230111T113431Z
UID:36220-1682985600-1683244799@www.pharmajournalist.com
SUMMARY:4th Annual Gene Therapy Analytical Development Europe Summit 2023
DESCRIPTION:Uniting leading CMC\, Regulatory\, QC\, Analytical and Process Development experts\, the 4th Annual Gene Analytical Development Europe Summit is the industry’s definitive and only meeting focused on tackling the greatest analytical development challenges in the context of gene therapy drug development. \nHear from the likes of AstraZeneca\, MHRA\, Gyroscope\, REGENXBIO\, Biogen\, Spark Therapeutics\, and more across three days and two tracks of in-depth case studies\, interactive panel discussions\, dedicated Q&A time\, and highly appraised networking opportunities to meet and learn from the leaders of this pioneering field. \nDon’t miss the opportunity to network with 80+ analytical experts to overcome your analytical challenges encountered in every stage of the gene therapy development life cycle. \nTo know more visit: https://ter.li/q8u3rf
URL:https://www.pharmajournalist.com/event/4th-annual-gene-therapy-analytical-development-europe-summit-2023/
LOCATION:The Tower Hotel\, St. Katharine's Way\, London\, E1W 1LD\, United Kingdom
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230509
DTEND;VALUE=DATE:20230512
DTSTAMP:20260516T055807
CREATED:20230227T131842Z
LAST-MODIFIED:20230227T131842Z
UID:36691-1683590400-1683849599@www.pharmajournalist.com
SUMMARY:4th STING & TLR Targeting Therapies Summit
DESCRIPTION:Facilitating key conversations needed to drive forward the development of safe and effective innate stimulating immunotherapies\, the 4th STING & TLR Targeting Therapies Summit will take place\, for the first time ever in person\, in Boston on May 9-11\, 2023. \nView the official program here. \nExplore innate agonists from discovery to translation with the leaders in the space and gain insight into clinical updates\, unpack what went wrong with some failures like ADU-S100 and address critical challenges including driving down toxicity\, preclinical model selection and choosing appropriate delivery mechanisms. \nHere are some exciting highlights you cannot miss including: \n\nReviewing the clinical landscape in the past year\, key updates in innate agonists that have moved through the clinic\, and identifying the root of failed trials through integral discussions led by Beacon Targeted Therapies\, Tempest Therapeutics\, and #Indaptus Therapeutics\nAssessing the best innate agonist delivery approaches\, from data on antibody-conjugated STING agonists with Takeda Oncologyand ImmuneSensor to unpacking 7&8 Biopharma’s IV delivery to extracellular vesicle approaches with Codiak Bio \nRevisiting cancer vaccines and navigating their development with post-COVID vaccine considerations; with Elicio Therapeuticsand UT Southwestern Medicine\, exploring the use of STING / TLR adjuvants to deliver on this promising therapeutic\nVenturing beyond oncology to learn from drug developers utilizing STING & TLR agonists to treat infectious diseases and adding these potent innate activators to our arsenal to be better equipped for the next pandemic\n\nView the complete agenda and speaker line-up. \nBeing the only meeting dedicated to driving forward the development of innate immune agonists\, we encourage you to take this exciting opportunity to unite and leverage the industry’s cumulative knowledge and experience to have meaningful conversations that will translate STING & TLR agonists into effective and reliable treatment options.
URL:https://www.pharmajournalist.com/event/4th-sting-tlr-targeting-therapies-summit/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230510
DTEND;VALUE=DATE:20230512
DTSTAMP:20260516T055807
CREATED:20230323T113857Z
LAST-MODIFIED:20230323T113857Z
UID:36881-1683676800-1683849599@www.pharmajournalist.com
SUMMARY:Highly Potent Active Pharmaceutical Ingredients Conference 2023
DESCRIPTION:The Global High Potency API/HPAPI Market is projected to reach 37 billion USD by 2027\, growing at an ever-increasing CAGR of 8.43%. The expanding production of high potency APIs\, along with the increase in associated toxicities\, are driving requirements for more effective containment solutions and much-needed guidelines to ensure worker safety. \nOur 2023 conference brings insights from leading pharmaceutical companies on how to improve hazard identification\, integrate advanced containment controls and mitigate the risk of manufacturing HPAPI. Featuring leading speakers including directors\, engineers\, and experts in validation requirements this conference provides an extensive look at how you can futureproof your pharmaceutical manufacturing facilities. \nThis two-day conference offers you peer-to-peer networking with industry experts including heads and directors of EHS\, Occupational Hygiene\, Quality Assurance and more. Expand your community and explore the latest developments in the industry at this two-day event\, including key regulatory updates\, and leading case studies from leading pharmaceutical and biotechnology companies. \nBenefits of Attending the HPAPI Conference: \n\nLEARN how to ensure advanced therapeutic manufacturing is safe for workers and patients\nINCREASE the effectiveness of your engineering containment controls by improving harmony between the worker engineer and toxicologist to ensures cost-effective design choices\nUNCOVER the best practises & opportunities for pharmaceutical companies to work alongside CMOs to effectively and efficiently scale-up HPAPI manufacturing\nREVIEW case studies on the implementation of risk-based hazard identification strategies from leading pharmaceutical companies including AstraZeneca\, CSL Behring and Merck\n\nDISCOVER future trends in containment and control technologies to future-proof your HPAPI manufacturing plant to maximsie operator safety \nTo know more visit: www.highlypotentapi.com/PharmaJournalistEL
URL:https://www.pharmajournalist.com/event/highly-potent-active-pharmaceutical-ingredients-conference-2023/
LOCATION:Copthorne Tara Hotel\, Scarsdale Place\, Kensington\, London\, W8 5SY\, United Kingdom
ORGANIZER;CN="SAE Media Group":MAILTO:events@saemediagroup.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230510
DTEND;VALUE=DATE:20230512
DTSTAMP:20260516T055807
CREATED:20230323T114213Z
LAST-MODIFIED:20230323T114213Z
UID:36887-1683676800-1683849599@www.pharmajournalist.com
SUMMARY:5th Annual Injectable Drug Delivery Conference
DESCRIPTION:Exploring Injectable Drug Formulations and Device Development \nSponsors: Victrex \nExhibitors: PHC Group  \nAs Part of Europe’s leading Injectable conference series\, the 5th annual Injectable Drug Delivery conference will assess innovations in drug product formulation and biologics\, new technologies in device design\, along with the latest regulatory considerations for optimal drug delivery. \n \nWith increasing demand for vaccines\, insulin\, and many other modern medicines administered via the injectable route\, there is significant growth projected in the biologics market\, particularly the injectable drug delivery and prefilled syringe market which is expected to rise at a compound annual growth rate of 12.9% reaching £915 billion by 2027. It is due to this rising demand and increased growth that the industry must come together to discuss and critically evaluate the next generation of injectable drug delivery. \nAt this year’s event we will highlight the most recent innovations within the industry\, with regard to injectable device design and the formulation challenges of long-lasting\, highly viscous and high-volume drug delivery. In silico modelling will be addressed as we continue to see a move towards AI utilisation\, alongside key CMC concerns and usability of injectable devices in digital health. The conference will also highlight the significance of sustainability within the industry\, whilst providing regulatory insight on the changes that have occurred and are forecast in the coming years. \nBenefits of attending: \n\nExplore the latest trends within the Injectable drug delivery field\, with new insights into in-silico modelling\nExpand on current knowledge of device design\, with special considerations for primary and secondary packaging\nExamine injectable drug formulation strategies\, including novel formulation methodologies\nLearn how to advance the injectable drug delivery landscape through a review of current regulatory compliance\nRealise how Chemical Manufacturing and Control can further expand the industry through digitalisation strategies\n\nTo know more visit: http://www.injectable-drug-delivery.com/PharmaJournalist-EI
URL:https://www.pharmajournalist.com/event/5th-annual-injectable-drug-delivery-conference/
LOCATION:Copthorne Tara Hotel\, Scarsdale Place\, Kensington\, London\, W8 5SY\, United Kingdom
ORGANIZER;CN="SAE Media Group":MAILTO:events@saemediagroup.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230516
DTEND;VALUE=DATE:20230518
DTSTAMP:20260516T055807
CREATED:20221209T121926Z
LAST-MODIFIED:20221209T122048Z
UID:36016-1684195200-1684367999@www.pharmajournalist.com
SUMMARY:Reuters Events: Digital Health 2023
DESCRIPTION:It’s a painful moment for healthcare. We face rampant burn out\, squeezed operating margins\, unhappy patients\, massive cost pressures and more competition than ever as disruptors continue to flood the market with convenient\, accessible care options. \nIt’s high time we collaborate around Digital Health. We must listen\, take note and work to implement the changes that our care staff and consumers demand to force the disruptive change required. Fixing our broken healthcare system demands a collective effort to connect disparate data\, streamline clinical workflows\, slash costs\, and zero in on consumer orientated\, digitally enabled care delivery. \nReuters Events: Digital Health USA 2023 (May 16-17\, San Diego) hosts 300+ digital leaders over two intensive days of collaborating\, networking\, and learning opportunities tailored to digital\, strategy\, innovation\, transformation\, information\, information security\, data science backgrounds\, to help accelerate the transformation that our consumers desire and our care teams deserve. \nTo know more visit: https://bit.ly/3F7cD60
URL:https://www.pharmajournalist.com/event/reuters-events-digital-health-2023/
LOCATION:Mission Bay Resort\, 1775 E Mission Bay Dr.\, San Diego\, CA\, 92109\, United States
ORGANIZER;CN="Reuters Events":MAILTO:Natalie.Diaz-Martin@thomsonreuters.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230516
DTEND;VALUE=DATE:20230519
DTSTAMP:20260516T055807
CREATED:20230202T110613Z
LAST-MODIFIED:20230202T110719Z
UID:36466-1684195200-1684454399@www.pharmajournalist.com
SUMMARY:2nd ALS Drug Development Summit
DESCRIPTION:With 3 days of jam-packed content and 35+ world class speakers pioneering the next wave of ALS therapies\, the 2nd ALS Drug Development Summit is biopharma’s can’t-miss meeting for the acceleration of ALS drug development pipelines. \nJoin 100+ of your biopharma peers to uncover cutting-edge ALS biomarkers\, including neurofilament light chain\, to incorporate into clinical trials\, improve in vitro and in vivo ALS preclinical models to improve translation of safe and efficacious therapies and optimize clinical trial design and endpoints to maximise data collection in an evolving standard of care. \nBrowse the full Event Guide to discover:\n\n37+ expert ALS speakers across 3 jam-packed conference days\, spanning all stages of the drug development pipeline\n\n\nDoubled pre-conference workshop content\, with 4 deep-dive workshops facilitating interactive discussions on novel ALS target discovery\, preclinical strategy\, wearable technology\, and clinical trial design\n\n\nOpening conference discussion on recent and upcoming FDA approvals to learn key takeaways from interacting with regulatory bodies\n\n\nHear directly from patient advocates and individuals living with ALS to understand their perspective on ALS drug development and engagement in clinical research\n\n\nDedicated networking\, roundtable discussion and poster sessions to share your insights with other ALS leaders in the room\n\nTo know more visit: https://ter.li/21k4zy
URL:https://www.pharmajournalist.com/event/2nd-als-drug-development-summit/
LOCATION:Hilton Boston Logan Airport\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:Info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230530
DTEND;VALUE=DATE:20230602
DTSTAMP:20260516T055807
CREATED:20230222T124243Z
LAST-MODIFIED:20230222T124243Z
UID:36641-1685404800-1685663999@www.pharmajournalist.com
SUMMARY:5th Treg Summit
DESCRIPTION:With investment into the Treg field at an all time high\, excitement is overflowing at the prospect of these remarkable cells being game-changers in the long-term treatment of autoimmunity\, inflammation and transplantation. As this enthusiasm coincides with multiple clinical readouts and several more therapies entering the clinic\, it remains vital for Treg trailblazers to come together to recognize therapy efficacy\, determine safety and translate the next-generation of therapies into the clinic. \nThe Treg Summit returns for the 5th year to unite this dedicated community of industry and academic experts\, and remains the go-to industry forum to advance both cell and non-cell based approaches to unlock the potential of Tregs to treat indications with huge unmet clinical need. \nWith 3 jam-packed days of content across CAR-\, TCR– and polyclonal Tregs as well as IL-2\, muteins and small molecules\, you won’t want to miss this unrivalled opportunity to collaborate with your peers in the Treg field to explore clinical advances\, discuss challenges and discover next-gen methods to take Treg therapies to the next level. \nWhy Attend Now? \n\nOver $2 billion has been thrown into the Treg space in the past 8 months alone\, reflecting the potential of these therapies\n2022 saw the first-ever dosing of a human with a CAR-Treg cell therapy paving the way for the rest of the engineered Treg field\nVital clinical updates determine the safety and efficacy of Treg modulating therapies\n\nSecure your place today – https://ter.li/jddnbx
URL:https://www.pharmajournalist.com/event/5th-treg-summit/
LOCATION:Hyatt Regency Boston Downtown\, One Ave. de Lafayette\, Boston\, MA\, 02111\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230531
DTEND;VALUE=DATE:20230603
DTSTAMP:20260516T055807
CREATED:20230208T093703Z
LAST-MODIFIED:20230208T093703Z
UID:36555-1685491200-1685750399@www.pharmajournalist.com
SUMMARY:2nd Cell Therapy Potency Assay Summit
DESCRIPTION:The 2nd Cell Therapy Potency Assay will gather 100+ experts working to rationally design better potency assays to smooth the path to regulatory approval and minimize hold times with scientifically rigorous and informative potency measurements. \nWhether you are submitting your first IND or gearing up towards BLA submission\, this critical meeting of minds is your premier opportunity to join the likes of bluebird bio\, Arsenal Bio\, Takeda\, Merck\, Sana Biotechnology and more\, to gain critical updates on regulatory interactions and unpick how industry peers are approaching potency assay development. \nLeave this meeting equipped with industry insights to understand what potency assays are showing\, develop practical\, compatible\, reproducible assays; and better characterize your cell therapy products for targeted\, untargeted\, allogeneic and autologous platforms in oncology and non-oncology indications. \nTo know more visit: https://ter.li/zc871s
URL:https://www.pharmajournalist.com/event/2nd-cell-therapy-potency-assay-summit/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230531
DTEND;VALUE=DATE:20230603
DTSTAMP:20260516T055807
CREATED:20230307T092630Z
LAST-MODIFIED:20230307T092630Z
UID:36769-1685491200-1685750399@www.pharmajournalist.com
SUMMARY:5th Age-Related Disease Therapeutics Summit
DESCRIPTION:Whether it’s in cardiovascular disease\, Alzheimer’s or osteoarthritis\, therapeutic innovations to target the mechanisms of aging are making significant headway to clinical trials. With increased investments and recognition\, along with the escalation of the burden of age-related disease\, research and development to meet this unmet medical need has never been more important. \nThe 5th Age-Related Disease Therapeutics Summit is the only industry-focused meeting dedicated to uniting 100+ biopharma drug developers\, pioneering academics\, and prominent investors striving to develop effective\, novel drugs that promote healthy aging and overcome major translational and regulatory obstacles. \nJam-packed with the most cutting-edge insights and opportunities to reunite with and hear from your peers on the next steps forward in developing the safest and most efficacious drug to promote a healthier and enhanced quality of life. \nTo know more visit: https://ter.li/sl5og6
URL:https://www.pharmajournalist.com/event/5th-age-related-disease-therapeutics-summit/
LOCATION:Marines Memorial Club and Hotel\, 609 Sutter St\, San Francisco\, CA\, 94102\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR